13F Holdings
中文EN

CAPR CAPRICOR THERAPEUTICS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1133869 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-11.5%
TTM net income YoY-81.6%
TTM EPS YoY-38.6%
Revenue 3-yr CAGR349.7%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-191.1%
Net margin-181.7%
FCF margin-184.8%
EBITDA margin-184.7%

Returns

ROE-48.2%
ROA-35.3%
ROIC (approx.)-47.3%
Asset turnover0.19x

Leverage & solvency

Liabilities / assets14.7%
Debt / equity0.00x
Current ratio7.77x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.99x
Accruals ratio-0.4%
Payout ratio—
Capex / revenue5.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$0$22.27M$25.18M$2.55M$244,898
R&D expense$84.45M$49.97M$36.45M$21.82M$13.57M
SG&A expense$23.69M$14.87M$12.81M$10.43M$7.61M
Operating income-$108.14M-$42.56M-$24.08M-$29.70M-$20.94M
Interest expense$3.05M$0———
Pretax income-$105.04M-$40.47M———
Income tax$1,600$1,600———
Net income-$105.04M-$40.47M-$22.29M-$29.02M-$20.02M
EBITDA-$106.25M-$41.14M-$23.01M-$29.16M-$20.69M
EPS (basic)-2.26-1.15-0.83-1.18-0.87
EPS (diluted)-2.26-1.15-0.83-1.18-0.87
Weighted avg. shares (diluted)46.48M35.22M26.78M24.55M23.09M
Balance sheet
Cash & equivalents$287.85M$11.29M$14.69M$9.60M$34.89M
Short-term investments$30.28M$140.23M$24.79M$31.82M$0
Current assets$322.94M$163.39M$50.86M$42.89M$36.44M
PP&E, net$18.31M$5.56M$5.56M$4.59M$1.80M
Intangibles————$0
Total assets$355.95M$170.48M$58.73M$50.09M$41.33M
Current liabilities$35.84M$21.03M$31.27M$23.59M$4.13M
Total liabilities$50.16M$25.02M$36.13M$38.31M$9.96M
Shareholders' equity$305.79M$145.46M$22.60M$11.79M$31.37M
Shares outstanding57.37M45.58M31.15M25.24M24.19M
Cash flow statement
Operating cash flow-$69.81M-$40.00M-$25.60M$4.92M-$16.81M
Capital expenditure$2.90M$1.17M$1.31M$2.00M$1.20M
Free cash flow-$72.72M-$41.16M-$26.91M$2.92M-$18.01M
Investing cash flow$97.48M-$116.18M$5.11M-$35.07M-$1.20M
Financing cash flow$248.89M$152.77M$25.58M$4.87M$20.23M
Depreciation & amortization$1.89M$1.43M$1.07M$533,131$245,697
Stock-based compensation$17.23M$9.77M$7.39M$4.46M$2.97M

Free plan shows the latest 5 periods; Pro shows all 20 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.